{"id":10418,"date":"2023-04-28T18:15:00","date_gmt":"2023-04-28T16:15:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/"},"modified":"2023-04-28T18:15:00","modified_gmt":"2023-04-28T16:15:00","slug":"irlab-publicerar-arsredovisningen-for-2022","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/","title":{"rendered":"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

\n

G\u00f6teborg, Sverige, 28 april 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2022 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.<\/strong><\/p>\n<\/div>\n

\n

IRLAB\u00a0har idag publicerat \u00e5rsredovisning 2022 f\u00f6r r\u00e4kenskaps\u00e5ret 1 januari till 31 december 2022.\u00a0\u00c5rsredovisningen finns tillg\u00e4nglig p\u00e5 bolagets hemsida:\u00a0Finansiella rapporter \u2013 IRLAB<\/a>. En tryckt version av \u00e5rsredovisningen 2022 kommer finnas tillg\u00e4nglig fr\u00e5n och med slutet\u00a0av maj.<\/p>\n

Bolaget \u00e4ndrade publiceringsdatum f\u00f6r \u00e5rsredovisningen f\u00f6r att f\u00f6lja 16 kapitlet 4\u00a7 i Lag (2007:528) om v\u00e4rdepappersmarknaden, vilken stadgar att noterade bolag ska offentligg\u00f6ra sin \u00e5rsredovisning senast fyra m\u00e5nader efter utg\u00e5ngen av r\u00e4kenskaps\u00e5ret.<\/p>\n<\/div>\n

\n

F\u00f6r mer information<\/strong><\/p>\n

\n

Gunnar Olsson, VD
Tel: +46 70 576 14 02
E-post: gunnar.olsson@irlab.se<\/a><\/p>\n

Viktor Siewertz, CFO
Tel: +46 727 10 70 70
E-post:\u00a0viktor.siewertz@irlab.se<\/a><\/p>\n<\/div>\n

\n

Denna information \u00e4r s\u00e5dan information som IRLAB Therapeutics \u00e4r skyldigt att offentligg\u00f6ra enligt lagen om v\u00e4rdepappersmarknaden. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2023-04-28 18:15 CEST.<\/em><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar nya l\u00e4kemedel f\u00f6r behandling av Parkinsons sjukdom och andra sjukdomar i hj\u00e4rnan. Bolagets l\u00e4ngst framskridna l\u00e4kemedelskandidater, mesdopetam (IRL790) och pirepemat (IRL752) \u00e4r b\u00e5da i Fas IIb och \u00e4r designade f\u00f6r att behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinson. \u00c5r 2021 f\u00f6rv\u00e4rvade Ipsen, ett specialty pharma-bolag, de exklusiva globala r\u00e4ttigheterna till utveckling och kommersialisering av mesdopetam.
\u00a0
IRLAB har genererat alla sina l\u00e4kemedelskandidater och forts\u00e4tter att uppt\u00e4cka innovativa l\u00e4kemedelskandidater f\u00f6r behandling av neurologiska sjukdomar genom den egenutvecklade forskningsplattformen ISP (Integrative Screening Process). F\u00f6rutom IRLAB:s starka kliniska pipeline driver bolaget tre prekliniska program, IRL942, IRL757 och IRL1117, mot Fas I-studier. IRLAB \u00e4r noterat p\u00e5 Nasdaq Stockholm. Mer information p\u00e5\u00a0www.irlab.se.<\/a><\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB \u00c5rsredovisning 2022<\/a>
549300JAT34LHEI0DH60-2022-12-31-sv<\/a>
549300JAT34LHEI0DH60-2022-12-31-sv<\/a><\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, Sverige, 28 april 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2022 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.<\/p>\n","protected":false},"template":"","class_list":["post-10418","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-annual_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-regulatory-vpml_sv"],"acf":[],"yoast_head":"\nIRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, Sverige, 28 april 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2022 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/\",\"name\":\"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2023-04-28T16:15:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022 - IRLAB","og_description":"G\u00f6teborg, Sverige, 28 april 2023 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett bolag som uppt\u00e4cker och utvecklar nya behandlingar vid Parkinsons sjukdom, meddelade idag att bolagets \u00e5rsredovisning f\u00f6r 2022 finns tillg\u00e4nglig p\u00e5 bolags webbplats, www.irlab.se.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/","name":"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2023-04-28T16:15:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-publicerar-arsredovisningen-for-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB publicerar \u00e5rsredovisningen f\u00f6r 2022"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/10418","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=10418"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}